Literature DB >> 8947861

On the feasibility of real-time, in vivo harmonic imaging with proteinaceous microspheres.

F Forsberg1, B B Goldberg, J B Liu, D A Merton, N M Rawool.   

Abstract

Harmonic imaging is a new contrast-specific imaging modality, which utilizes the nonlinear properties of microbubble-based sonographic contrast agents by transmitting at the fundamental frequency but receiving at the second harmonic frequency. The feasibility of improving the detection of slow, small-volume blood flow using real-time harmonic imaging has been investigated in vivo. Proteinaceous microspheres (FS069) were administrated to four dogs, two woodchucks (with multiple hepatomas), and one rabbit. Three different scanners were used to obtain real-time images of kidneys and liver (including vessels) in harmonic and conventional gray scale and color flow modes. The duration of contrast enhancement lasted significantly longer in harmonic than in conventional modes (on average 87 s; P = 0.008). Harmonic images were less susceptible to artifacts, such as acoustic shadowing, and a clear increase in the (flow) signal-to-noise ratio was observed. These preliminary in vivo results demonstrate the feasibility of performing real-time, contrast-enhanced harmonic imaging, but further studies are required to establish clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947861     DOI: 10.7863/jum.1996.15.12.853

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  12 in total

1.  Evaluation of myocardial, hepatic, and renal perfusion in a variety of clinical conditions using an intravenous ultrasound contrast agent (Optison) and second harmonic imaging.

Authors:  J Hancock; H Dittrich; D E Jewitt; M J Monaghan
Journal:  Heart       Date:  1999-06       Impact factor: 5.994

2.  Improving the sensitivity of high-frequency subharmonic imaging with coded excitation: a feasibility study.

Authors:  Himanshu Shekhar; Marvin M Doyley
Journal:  Med Phys       Date:  2012-04       Impact factor: 4.071

3.  Contrast-enhanced ultrasound imaging of prostate cancer.

Authors:  Ethan J Halpern
Journal:  Rev Urol       Date:  2006

4.  Modifying the size distribution of microbubble contrast agents for high-frequency subharmonic imaging.

Authors:  Himanshu Shekhar; Joshua J Rychak; Marvin M Doyley
Journal:  Med Phys       Date:  2013-08       Impact factor: 4.071

5.  Contrast-enhanced multiphase dynamic ultrasonography for the characterization of liver tumors.

Authors:  Sachiko Tanaka; Yoshihiro Hamada; Tatsuya Ioka; Takashi Sugiyama; Iwao Akamatsu; Rena Takakura; Fumi Yoshioka; Akihiko Nakaizumi; Tetsushi Ishida
Journal:  J Med Ultrason (2001)       Date:  2005-06       Impact factor: 1.314

Review 6.  Evolving clinical applications of contrast-enhanced ultrasound (CEUS) in the abdominal aorta.

Authors:  Vasileios Rafailidis; Sasan Partovi; Alexander Dikkes; Dean A Nakamoto; Nami Azar; Daniel Staub
Journal:  Cardiovasc Diagn Ther       Date:  2018-04

7.  Parametric subharmonic imaging using a commercial intravascular ultrasound scanner: an in vivo feasibility study.

Authors:  John R Eisenbrey; Anush Sridharan; Ebo D deMuinck; Marvin M Doyley; Flemming Forsberg
Journal:  J Ultrasound Med       Date:  2012-03       Impact factor: 2.153

8.  The delayed onset of subharmonic and ultraharmonic emissions from a phospholipid-shelled microbubble contrast agent.

Authors:  Himanshu Shekhar; Ivy Awuor; Keri Thomas; Joshua J Rychak; Marvin M Doyley
Journal:  Ultrasound Med Biol       Date:  2014-04       Impact factor: 2.998

9.  Delineation of atherosclerotic plaque using subharmonic imaging filtering techniques and a commercial intravascular ultrasound system.

Authors:  Anush Sridharan; John R Eisenbrey; Priscilla Machado; Ebo D deMuinck; Marvin M Doyley; Flemming Forsberg
Journal:  Ultrason Imaging       Date:  2013-01       Impact factor: 1.578

10.  [Breast cancer. Sonography and magnetic resonance mammography].

Authors:  S Delorme
Journal:  Radiologe       Date:  2004-06       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.